Solvay viewing options for pharma

31 May 2009

MedImmune, the USA-based worldwide biologics business of Anglo-Swedish drug major AstraZeneca says that the Department of Health and Human  Services (HHS) has awarded it a contract to manufacture monovalent  (single-strain) live attenuated influenza vaccine for Novel Influenza A  (H1N1) to vaccinate priority populations identified by HHS in the  National Strategy for Pandemic Influenza. An initial order of $90.0  million of vaccine has been placed, with the potential for more. This  project has been funded in whole or in part with the Federal funds from  HHS/ASPR/BARDA, under Contract number HHSO100200900002I.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight